|
||||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: ENSG00000141526 |
Summary for SLC16A3 |
Gene summary |
| Gene information | Ensembl ID | ENSG00000141526 | Gene symbol | SLC16A3 |
| Gene name | solute carrier family 16 member 3 | |
| HGNC | 10924 | |
| Entrez ID | 9123 | |
| Gene type | protein_coding | |
| Synonyms | SLC16A3|MCT3|MCT4 | |
| UniProtAcc | O15427 |
Drugs associated with this gene(DrugBank). |
| Gene ID | Gene Symbol | Drug ID | Drug Name | Drug Type |
| ENSG00000141526 | SLC16A3 | DB00119 | Pyruvic acid | SmallMoleculeDrug |
Cancer therapeutic drugs associated with this gene(NCI). |
| Gene ID | Gene Name | Drug ID | Drug Name | Drug Type | Cancer |
Top |
Structure and expression level for SLC16A3 |
AS events and RNA A-to-I editing events of the gene in TCGA based on Genvode V22 structure.∗For more information on exon skipping events please check the ExonskipDB database. ∗For more information on exon skipping events please check the CAeditome database. |
Landscape of gene expressions across multiple cancer types. |
Differentially expressed gene analysis between tumor male and tumor female samples. |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
Differentially expressed gene analysis between tumor male and normal male samples. |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| SLC16A3 | 8.10e+03 | 1.45e+00 | 3.74e-01 | 3.87e+00 | 1.08e-04 | 4.77e-04 | BLCA |
| SLC16A3 | 5.89e+03 | 1.35e+00 | 3.06e-01 | 4.42e+00 | 9.80e-06 | 1.52e-04 | ESCA |
| SLC16A3 | 2.64e+03 | 2.97e+00 | 5.81e-01 | 5.12e+00 | 3.09e-07 | 2.47e-06 | CHOL |
Differentially expressed gene analysis between tumor female and normal female samples. |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| SLC16A3 | 7.11e+03 | 1.05e+00 | 2.56e-01 | 4.10e+00 | 4.11e-05 | 1.23e-04 | LUSC |
| SLC16A3 | 2.66e+03 | 2.22e+00 | 1.19e-01 | 1.87e+01 | 7.56e-78 | 1.65e-76 | BRCA |
Top |
Sex-biased somatic mutation for SLC16A3 |
| ∗For more information on exon skipping events please check the ExonskipDB database. |
| Gene ID | Cancer Type | Hugo Symbol | Male | Female | pval | or | ci.up | ci.low | adjPval |
Top |
DNA methylation with beta values for SLC16A3 |
Landscape of DNA methylation across multiple cancer types. |
Differentially expressed CpG sites between male tumor and female tumor patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| BRCA | cg04184297 | chr17:82228390 | CGI:chr17:82228259-82232114 | promoter | 6.47e-01 | 8.18e-01 | -3.16e+00 | 1.60e-03 | 1.22e-02 | -1.71e-01 |
| BRCA | cg14654468 | chr17:82228460 | CGI:chr17:82228259-82232114 | UTR,promoter,exon,gene body | 6.34e-01 | 8.12e-01 | -3.05e+00 | 2.31e-03 | 1.46e-02 | -1.78e-01 |
| BRCA | cg08296680 | chr17:82228399 | CGI:chr17:82228259-82232114 | UTR,promoter,exon,gene body | 6.43e-01 | 8.19e-01 | -2.69e+00 | 7.11e-03 | 2.34e-02 | -1.76e-01 |
| BRCA | cg14417329 | chr17:82228397 | CGI:chr17:82228259-82232114 | promoter | 6.52e-01 | 7.70e-01 | -2.16e+00 | 3.04e-02 | 4.12e-02 | -1.18e-01 |
| KIRC | cg04184297 | chr17:82228390 | CGI:chr17:82228259-82232114 | promoter | 4.34e-01 | 3.29e-01 | 4.87e+00 | 1.09e-06 | 8.43e-06 | 1.05e-01 |
| KIRC | cg14654468 | chr17:82228460 | CGI:chr17:82228259-82232114 | UTR,promoter,exon,gene body | 3.84e-01 | 2.78e-01 | 4.52e+00 | 6.14e-06 | 4.37e-05 | 1.06e-01 |
| KIRC | cg08296680 | chr17:82228399 | CGI:chr17:82228259-82232114 | UTR,promoter,exon,gene body | 4.11e-01 | 2.82e-01 | 5.00e+00 | 5.68e-07 | 4.49e-06 | 1.29e-01 |
| KIRC | cg14417329 | chr17:82228397 | CGI:chr17:82228259-82232114 | promoter | 4.75e-01 | 3.63e-01 | 5.08e+00 | 3.77e-07 | 3.02e-06 | 1.12e-01 |
| SARC | cg04184297 | chr17:82228390 | CGI:chr17:82228259-82232114 | promoter | 6.09e-01 | 4.84e-01 | 3.88e+00 | 1.04e-04 | 5.30e-04 | 1.25e-01 |
| SARC | cg14654468 | chr17:82228460 | CGI:chr17:82228259-82232114 | UTR,promoter,exon,gene body | 5.77e-01 | 4.46e-01 | 3.72e+00 | 1.98e-04 | 9.24e-04 | 1.32e-01 |
| SARC | cg08296680 | chr17:82228399 | CGI:chr17:82228259-82232114 | UTR,promoter,exon,gene body | 5.98e-01 | 4.52e-01 | 3.87e+00 | 1.09e-04 | 5.52e-04 | 1.46e-01 |
Differentially expressed CpG sites between male tumor and male normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| KIRC | cg04184297 | chr17:82228390 | CGI:chr17:82228259-82232114 | promoter | 3.29e-01 | 4.51e-01 | -3.35e+00 | 8.08e-04 | 1.29e-03 | -1.23e-01 |
| KIRC | cg08296680 | chr17:82228399 | CGI:chr17:82228259-82232114 | UTR,promoter,exon,gene body | 2.82e-01 | 3.82e-01 | -2.29e+00 | 2.17e-02 | 2.38e-02 | -1.00e-01 |
| KIRC | cg14417329 | chr17:82228397 | CGI:chr17:82228259-82232114 | promoter | 3.63e-01 | 4.94e-01 | -3.36e+00 | 7.86e-04 | 1.26e-03 | -1.32e-01 |
| HNSC | cg21453758 | chr17:82228067 | CGI:chr17:82228259-82232114 | promoter | 8.60e-01 | 9.61e-01 | -3.93e+00 | 8.64e-05 | 2.29e-04 | -1.01e-01 |
| HNSC | cg18345635 | chr17:82228204 | CGI:chr17:82228259-82232114 | promoter | 4.08e-01 | 5.25e-01 | -4.07e+00 | 4.73e-05 | 1.38e-04 | -1.17e-01 |
| HNSC | cg10183885 | chr17:82230010 | CGI:chr17:82228259-82232114 | promoter,exon,gene body | 6.83e-01 | 8.14e-01 | -3.97e+00 | 7.30e-05 | 1.99e-04 | -1.31e-01 |
| HNSC | cg01944226 | chr17:82230180 | CGI:chr17:82228259-82232114 | promoter,exon,gene body | 7.15e-01 | 8.38e-01 | -2.96e+00 | 3.05e-03 | 4.68e-03 | -1.23e-01 |
| LUSC | cg10183885 | chr17:82230010 | CGI:chr17:82228259-82232114 | promoter,exon,gene body | 6.69e-01 | 8.35e-01 | -3.59e+00 | 3.32e-04 | 1.29e-03 | -1.66e-01 |
| LUSC | cg01944226 | chr17:82230180 | CGI:chr17:82228259-82232114 | promoter,exon,gene body | 7.00e-01 | 8.59e-01 | -2.86e+00 | 4.25e-03 | 7.22e-03 | -1.59e-01 |
| BLCA | cg21453758 | chr17:82228067 | CGI:chr17:82228259-82232114 | promoter | 8.48e-01 | 9.67e-01 | -4.24e+00 | 2.22e-05 | 1.48e-04 | -1.19e-01 |
| BLCA | cg08296680 | chr17:82228399 | CGI:chr17:82228259-82232114 | UTR,promoter,exon,gene body | 7.43e-02 | 1.92e-01 | -4.02e+00 | 5.78e-05 | 2.73e-04 | -1.18e-01 |
| BLCA | cg23141183 | chr17:82227442 | CGI:chr17:82228259-82232114 | promoter | 8.13e-01 | 9.21e-01 | -4.25e+00 | 2.11e-05 | 1.44e-04 | -1.08e-01 |
| BLCA | cg18345635 | chr17:82228204 | CGI:chr17:82228259-82232114 | promoter | 3.85e-01 | 5.46e-01 | -4.09e+00 | 4.27e-05 | 2.23e-04 | -1.61e-01 |
| KIRP | cg07763231 | chr17:82229473 | CGI:chr17:82228259-82232114 | promoter,exon,gene body | 2.76e-01 | 4.78e-01 | -4.29e+00 | 1.79e-05 | 6.09e-05 | -2.02e-01 |
| CHOL | cg10183885 | chr17:82230010 | CGI:chr17:82228259-82232114 | promoter,exon,gene body | 7.76e-01 | 8.85e-01 | -2.80e+00 | 5.09e-03 | 1.63e-02 | -1.09e-01 |
Differentially expressed CpG sites between female tumor and female normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| BRCA | cg04184297 | chr17:82228390 | CGI:chr17:82228259-82232114 | promoter | 6.47e-01 | 5.37e-01 | 6.95e+00 | 3.61e-12 | 1.06e-11 | 1.10e-01 |
| BRCA | cg14654468 | chr17:82228460 | CGI:chr17:82228259-82232114 | UTR,promoter,exon,gene body | 6.34e-01 | 4.81e-01 | 8.47e+00 | 2.44e-17 | 1.07e-16 | 1.53e-01 |
| BRCA | cg08296680 | chr17:82228399 | CGI:chr17:82228259-82232114 | UTR,promoter,exon,gene body | 6.43e-01 | 4.83e-01 | 7.69e+00 | 1.48e-14 | 5.23e-14 | 1.60e-01 |
| LUAD | cg18345635 | chr17:82228204 | CGI:chr17:82228259-82232114 | promoter | 4.14e-01 | 5.47e-01 | -3.52e+00 | 4.26e-04 | 1.87e-03 | -1.33e-01 |
| THCA | cg08296680 | chr17:82228399 | CGI:chr17:82228259-82232114 | UTR,promoter,exon,gene body | 6.29e-01 | 5.01e-01 | 4.84e+00 | 1.28e-06 | 7.60e-06 | 1.27e-01 |
| COAD | cg07763231 | chr17:82229473 | CGI:chr17:82228259-82232114 | promoter,exon,gene body | 1.99e-01 | 3.11e-01 | -3.28e+00 | 1.02e-03 | 3.03e-03 | -1.13e-01 |
| COAD | cg10183885 | chr17:82230010 | CGI:chr17:82228259-82232114 | promoter,exon,gene body | 6.97e-01 | 8.12e-01 | -2.22e+00 | 2.67e-02 | 3.19e-02 | -1.14e-01 |
| BLCA | cg10183885 | chr17:82230010 | CGI:chr17:82228259-82232114 | promoter,exon,gene body | 6.62e-01 | 7.82e-01 | -2.62e+00 | 8.69e-03 | 1.59e-02 | -1.20e-01 |
| KIRP | cg04184297 | chr17:82228390 | CGI:chr17:82228259-82232114 | promoter | 6.08e-01 | 4.75e-01 | 2.34e+00 | 1.91e-02 | 2.60e-02 | 1.34e-01 |
Top |
Exon skipping events with PSI in TCGA for SLC16A3 |
| ∗Please access ExonSkipDB for exon skipping annotation. |
Landscape of exon skipping events across multiple cancer types. |
Differentially expressed exon skipping events between male tumor and female tumor patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
Differentially expressed exon skipping events between male tumor and male normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
Differentially expressed exon skipping events between female tumor and female normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
Top |
RNA A-to-I editing events in TCGA for SLC16A3 |
| ∗Please access CAeditome for RNA editing annotation. |
Differentially expressed RNA editing events between male tumor and female tumor patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
Differentially expressed RNA editing events between male tumor and male normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
Differentially expressed RNA editing events between female tumor and female normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
Protein coding RNA editing(s). |
| Editing Position | Variant Type | Gene Symbol | Transcript ID | NTchange | AAchange |
Top |
Sex-biased TF-Gene network for SLC16A3 |
TFs related to SLC16A3.∗The female-biased TF-gene edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased TF-gene edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
| Cancer Type | TF | Target Gene | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
SLC16A3 related gene.∗Only the gene encode TF might with this result. ∗For more information please check Sex-biased TF-Coding gene network. |
Top |
Sex-biased RBP-ES network for SLC16A3 |
RBPs related to ES in SLC16A3.∗The female-biased RBP-ES edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased RBP-ES edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
| Cancer Type | RBP | Target ES | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| DLBC | BRUNOL6 | exon_skip_284657 | 8.86e+00 | 9.87e-01 | 8.49e+00 | 7.47e-03 | Male-biased |
| SARC | BRUNOL6 | exon_skip_284657 | 8.51e+00 | 1.11e-02 | 8.86e+00 | 9.84e-01 | Female-biased |
SLC16A3 related ES.∗Only the gene encode RBP might with this result. ∗For more information please check Sex-biased RBP-ES network in cancer. |
Top |
Sex-biased CeRNA regulation of gene |
Sex-biased CeRNA regulation of gene. |
| Gene ID | ceRNA(lncRNA-miRNA-mRNA) | Group | Cancer Type |
Top |
Sex-biased eQTL regulation of gene |
Sex-biased eQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| eQTL | Description |
Male-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs111598470 | chr17:75378276:G:C | - | 0.181902364010437 | 0.000166109304087893 | PCPG | Female-baised eQTL |
| rs60405814 | chr17:75391515:A:T | - | 0.15357518488931 | 0.00381786855268199 | PCPG | Female-baised eQTL |
| rs7208112 | chr17:75401732:T:C | - | 0.15357518488931 | 0.00381786855268199 | PCPG | Female-baised eQTL |
| rs67010935 | chr17:75370960:G:A | - | 0.145776551021822 | 0.00800502988764699 | PCPG | Female-baised eQTL |
| rs55772302 | chr17:75309755:T:A | - | 0.125787732983932 | 0.015391289337136 | PCPG | Female-baised eQTL |
| rs56001068 | chr17:75309756:C:A | - | 0.125787732983932 | 0.015391289337136 | PCPG | Female-baised eQTL |
| rs2165996 | chr17:79899721:C:T | - | 0.185053330371373 | 0.0343917597820227 | KIRP | Female-baised eQTL |
| rs4287602 | chr17:79898549:C:A | - | 0.119317930984606 | 0.0453672259531187 | STAD | Female-baised eQTL |
| rs7503434 | chr17:79898751:G:T | - | 0.119317930984606 | 0.0453672259531187 | STAD | Female-baised eQTL |
| rs35277255 | chr17:79899259:A:C | - | 0.119317930984606 | 0.0453672259531187 | STAD | Female-baised eQTL |
| rs34445789 | chr17:79899365:G:A | - | 0.119317930984606 | 0.0453672259531187 | STAD | Female-baised eQTL |
| rs113569170 | chr17:79900879:G:A | - | 0.118989033372323 | 0.046691149193458 | STAD | Female-baised eQTL |
| rs4374197 | chr17:79898453:G:C | - | 0.118882059551037 | 0.047905028885259 | STAD | Female-baised eQTL |
| rs74002917 | chr17:79325797:C:T | - | 0.0965169223878952 | 0.0010370823289244 | LGG | Female-baised eQTL |
| rs7219452 | chr17:79325051:A:C | - | 0.0867874586693961 | 0.00513085929944796 | LGG | Female-baised eQTL |
| rs57146709 | chr17:79324860:A:T | - | 0.0848895419469441 | 0.00719426393150685 | LGG | Female-baised eQTL |
| rs112978860 | chr17:81839485:C:T | - | 0.0765981049809852 | 0.0218584149892927 | LGG | Female-baised eQTL |
| rs113775324 | chr17:81844579:A:G | - | 0.0724787169732856 | 0.0357864746909593 | LGG | Female-baised eQTL |
| rs2070871 | chr17:81847258:G:A | - | 0.0721380104272548 | 0.0361170213652003 | LGG | Female-baised eQTL |
| rs111368292 | chr17:81858803:G:A | - | 0.0726805359910823 | 0.0384564219700116 | LGG | Female-baised eQTL |
| rs35170948 | chr17:81865726:C:T | - | 0.072929469607847 | 0.0385176193024221 | LGG | Female-baised eQTL |
| rs3786149 | chr17:81853470:A:G | - | 0.0725981912314595 | 0.0393625317823224 | LGG | Female-baised eQTL |
| rs113099800 | chr17:81851225:C:T | - | 0.0725968111186405 | 0.039374980755479 | LGG | Female-baised eQTL |
| rs34856581 | chr17:81833916:G:A | - | 0.0719114904325474 | 0.0397335310001926 | LGG | Female-baised eQTL |
| rs111308799 | chr17:81835061:G:A | - | 0.0719114904325474 | 0.0397335310001926 | LGG | Female-baised eQTL |
| rs112660052 | chr17:81835507:G:A | - | 0.0719114904325474 | 0.0397335310001926 | LGG | Female-baised eQTL |
| rs112584408 | chr17:81837797:G:C | - | 0.0719114904325474 | 0.0397335310001926 | LGG | Female-baised eQTL |
| rs4796839 | chr17:81838876:G:A | - | 0.0719114904325474 | 0.0397335310001926 | LGG | Female-baised eQTL |
| rs112934134 | chr17:81839924:G:A | - | 0.0719114904325474 | 0.0397335310001926 | LGG | Female-baised eQTL |
| rs35649520 | chr17:81845557:G:A | - | 0.0719114904325474 | 0.0397335310001926 | LGG | Female-baised eQTL |
| rs4796849 | chr17:81856860:G:C | - | 0.0724611393091558 | 0.0403529030156374 | LGG | Female-baised eQTL |
| rs3786150 | chr17:81858024:C:T | - | 0.0724611393091558 | 0.0403529030156374 | LGG | Female-baised eQTL |
| rs3786151 | chr17:81858065:C:T | - | 0.0724611393091558 | 0.0403529030156374 | LGG | Female-baised eQTL |
| rs11558886 | chr17:81860384:G:T | - | 0.0727071723942536 | 0.0404326586788956 | LGG | Female-baised eQTL |
| rs111370076 | chr17:81861402:C:G | - | 0.0727071723942536 | 0.0404326586788956 | LGG | Female-baised eQTL |
| rs113437492 | chr17:81863391:G:T | - | 0.0727071723942536 | 0.0404326586788956 | LGG | Female-baised eQTL |
| rs8069935 | chr17:72558179:G:C | - | 0.0611984711785566 | 0.0405655295413931 | LGG | Female-baised eQTL |
| rs111839893 | chr17:81848714:C:G | - | 0.0717897120495781 | 0.0419735786905771 | LGG | Female-baised eQTL |
| rs8324 | chr17:81843412:C:A | - | 0.0714464220933506 | 0.0422076543849389 | LGG | Female-baised eQTL |
| rs36035278 | chr17:81841379:G:A | - | 0.0717287071961266 | 0.0429255474333945 | LGG | Female-baised eQTL |
| rs11652950 | chr17:81872429:T:G | - | 0.0738486897549327 | 0.0431975433672029 | LGG | Female-baised eQTL |
| rs113194323 | chr17:81836328:A:C | - | 0.0710541009796992 | 0.0473106813711996 | LGG | Female-baised eQTL |
| rs111782781 | chr17:81836336:C:T | - | 0.0710541009796992 | 0.0473106813711996 | LGG | Female-baised eQTL |
| rs111562118 | chr17:81836392:C:T | - | 0.0710541009796992 | 0.0473106813711996 | LGG | Female-baised eQTL |
| rs111818389 | chr17:81836438:G:A | - | 0.0710541009796992 | 0.0473106813711996 | LGG | Female-baised eQTL |
| rs149722722 | chr17:81838648:A:C | - | 0.0710541009796992 | 0.0473106813711996 | LGG | Female-baised eQTL |
| rs9675127 | chr17:81827640:T:G | - | 0.0709707663034923 | 0.0485379961497055 | LGG | Female-baised eQTL |
| rs113604409 | chr17:81873657:C:T | - | 0.0732377854527165 | 0.0489446627162718 | LGG | Female-baised eQTL |
| rs112680942 | chr17:81874999:C:T | - | 0.0732377854527165 | 0.0489446627162718 | LGG | Female-baised eQTL |
| rs111276856 | chr17:81875615:T:C | - | 0.0732377854527165 | 0.0489446627162718 | LGG | Female-baised eQTL |
| rs35731743 | chr17:81876586:T:A | - | 0.0732377854527165 | 0.0489446627162718 | LGG | Female-baised eQTL |
| rs71377863 | chr17:72616205:C:T | - | 0.167422489050951 | 0.0314913749514813 | KIRC | Female-baised eQTL |
| rs34143788 | chr17:82948111:C:T | - | 0.184815010265702 | 0.0158836514697318 | BLCA | Female-baised eQTL |
Female-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs113875984 | chr17:74586507:C:G | - | -0.109419296763285 | 0.0223392062654476 | BLCA | Male-baised eQTL |
| rs4789513 | chr17:77914020:C:T | - | 0.0874182271451937 | 0.0403385867246365 | COAD | Male-baised eQTL |
Opposite sex-biased eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Sex-biased Gene in Cancer | Cancer Type |
Top |
Sex-biased eQTM regulation of gene |
Sex-biased eQTM regulation of gene (The figures only show the pairs with FDR<1e-5. For more information please check the below table). |
Male-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| cg10183885 | chr17:82230010 | gene,exon,promoter | -0.204750072661698 | 6.33380895525975e-10 | -0.4783037273608715 | 6.915283889897738e-13 | KIRP |
| cg01944226 | chr17:82230180 | gene,exon,promoter | -0.387995365290587 | 1.0902929980497e-15 | -0.49893994237771994 | 8.723145570231703e-20 | SKCM |
| cg10183885 | chr17:82230010 | gene,exon,promoter | -0.291021751555603 | 8.78442386870162e-13 | -0.45375848259139595 | 3.0913115561540084e-16 | SKCM |
| cg01731500 | chr17:82234361 | gene,exon,UTR | -0.439248394424262 | 1.82949427142554e-09 | -0.4016106074340138 | 9.611156536925698e-13 | SKCM |
| cg17817350 | chr17:82237861 | gene,exon,CDS | -0.439248394424262 | 1.82949427142554e-09 | -0.4016106074340138 | 9.611156536925698e-13 | SKCM |
| cg14417329 | chr17:82228397 | promoter | -0.0770945907499559 | 5.59502910549008e-06 | -0.31911023598503807 | 2.46073605746869e-08 | SKCM |
Female-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
Opposite sex-biased eQTM regulation. |
| CpG Site | CpG Postion | CpG Island | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Male Cor | Male P-value | Female Cor | Female P-value | Sex-biased Coding Gene | Cancer Type |
Top |
Sex-biased sQTL regulation of gene |
Sex-biased sQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTL | Description |
Male-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
Female-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
Opposite sex-biased sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Male Effect | Male FDR | Female Effect | Female FDR | Cancer Type |
Top |
Sex-biased sQTM regulation of gene |
Sex-biased sQTM regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTM | Description |
Male-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
Female-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
Opposite sex-biased sQTM regulation. |
| EX ID | EX Info | Skipped Exon | CPG Site | CPG Position | CPG Island | Position to EX Events | Male Effect | Male FDR | Female Effect | Female FDR | Male Correlation | Male P-value | Female Correlation | Female P-value | ORF_anno | Cancer Type |
Top |
Related disease information of SLC16A3 |
Diseases associated with this gene (DisGeNET). |
| Gene ID | Gene Symbol | Disease ID | Disease Name | Number of PMID | Source |
| ENSG00000141526 | SLC16A3 | C0006142 | Malignant neoplasm of breast | 1 | CTD_human |
| ENSG00000141526 | SLC16A3 | C0024623 | Malignant neoplasm of stomach | 1 | CTD_human |
| ENSG00000141526 | SLC16A3 | C0038356 | Stomach Neoplasms | 1 | CTD_human |
| ENSG00000141526 | SLC16A3 | C0678222 | Breast Carcinoma | 1 | CTD_human |
| ENSG00000141526 | SLC16A3 | C1257931 | Mammary Neoplasms, Human | 1 | CTD_human |
| ENSG00000141526 | SLC16A3 | C1458155 | Mammary Neoplasms | 1 | CTD_human |
| ENSG00000141526 | SLC16A3 | C1708349 | Hereditary Diffuse Gastric Cancer | 1 | CTD_human |
| ENSG00000141526 | SLC16A3 | C4704874 | Mammary Carcinoma, Human | 1 | CTD_human |